Literature DB >> 18483394

Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.

Robert W Chen1, Lynne T Bemis, Carol M Amato, Han Myint, Hung Tran, Diane K Birks, S Gail Eckhardt, William A Robinson.   

Abstract

Cyclin D1 (CCND1) is a well-known regulator of cell-cycle progression. It is overexpressed in several types of cancer including breast, lung, squamous, neuroblastoma, and lymphomas. The most well-known mechanism of overexpression is the t(11;14)(q13;q32) translocation found in mantle cell lymphoma (MCL). It has previously been shown that truncated CCND1 mRNA in MCL correlates with poor prognosis. We hypothesized that truncations of the CCND1 mRNA alter its ability to be down-regulated by microRNAs in MCL. MicroRNAs are a new class of abundant small RNAs that play important regulatory roles at the posttranscriptional level by binding to the 3' untranslated region (UTR) of mRNAs blocking either their translation or initiating their degradation. In this study, we have identified the truncation in CCND1 mRNA in MCL cell lines. We also found that truncated CCND1 mRNA leads to increased CCND1 protein expression and increased S-phase cell fraction. Furthermore, we demonstrated that this truncation alters miR-16-1 binding sites, and through the use of reporter constructs, we were able to show that miR-16-1 regulates CCND1 mRNA expression. This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483394      PMCID: PMC2481543          DOI: 10.1182/blood-2008-03-142182

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Authors:  Owen A O'Connor; Mark L Heaney; Lawrence Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria Richon; Paul Marks; William K Kelly
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

3.  Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization.

Authors:  Masayoshi Yasui; Hirofumi Yamamoto; Chew Yee Ngan; Bazarragchaa Damdinsuren; Yurika Sugita; Hiroki Fukunaga; Jinyu Gu; Makiko Maeda; Ichiro Takemasa; Masataka Ikeda; Yasushi Fujio; Mitsugu Sekimoto; Nariaki Matsuura; I Bernard Weinstein; Morito Monden
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

4.  Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin.

Authors:  Nobuhiko Oridate; Hyun-Jung Kim; Xiaochun Xu; Reuben Lotan
Journal:  Cancer Biol Ther       Date:  2005-03-23       Impact factor: 4.742

Review 5.  New directions in the treatment of mantle cell lymphoma: an overview.

Authors:  Andre Goy
Journal:  Clin Lymphoma Myeloma       Date:  2006-10

Review 6.  Update on the molecular biology of mantle cell lymphoma.

Authors:  Francesco Bertoni; Andrea Rinaldi; Emanuele Zucca; Franco Cavalli
Journal:  Hematol Oncol       Date:  2006-03       Impact factor: 5.271

7.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Richard I Fisher; Steven H Bernstein; Brad S Kahl; Benjamin Djulbegovic; Michael J Robertson; Sven de Vos; Elliot Epner; Amrita Krishnan; John P Leonard; Sagar Lonial; Edward A Stadtmauer; Owen A O'Connor; Hongliang Shi; Anthony L Boral; André Goy
Journal:  J Clin Oncol       Date:  2006-09-25       Impact factor: 44.544

8.  Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines.

Authors:  Jordi Camps; Itziar Salaverria; Maria J Garcia; Esther Prat; Sílvia Beà; Jessica C Pole; Lluis Hernández; Javier Del Rey; Juan Cruz Cigudosa; Marta Bernués; Carlos Caldas; Dolors Colomer; Rosa Miró; Elías Campo
Journal:  Leuk Res       Date:  2006-01-31       Impact factor: 3.156

9.  Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.

Authors:  Mary Grillo; Matthew J Bott; Neha Khandke; John P McGinnis; Miriam Miranda; Muthupalaniappan Meyyappan; Edward C Rosfjord; Sridhar K Rabindran
Journal:  Breast Cancer Res Treat       Date:  2005-12-01       Impact factor: 4.872

Review 10.  Cyclin D1: polymorphism, aberrant splicing and cancer risk.

Authors:  K E Knudsen; J Alan Diehl; C A Haiman; E S Knudsen
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  70 in total

Review 1.  The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.

Authors:  John R Finnerty; Wang-Xia Wang; Sébastien S Hébert; Bernard R Wilfred; Guogen Mao; Peter T Nelson
Journal:  J Mol Biol       Date:  2010-08-01       Impact factor: 5.469

Review 2.  miRNAs in normal and malignant B cells.

Authors:  Ai Kotani; Ratanakanit Harnprasopwat; Takae Toyoshima; Toyotaka Kawamata; Arinobu Tojo
Journal:  Int J Hematol       Date:  2010-07-08       Impact factor: 2.490

Review 3.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

4.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Authors:  Aldo M Roccaro; Antonio Sacco; Brian Thompson; Xavier Leleu; Abdel Kareem Azab; Feda Azab; Judith Runnels; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Charles P Lin; Domenico Ribatti; Barrett J Rollins; Thomas E Witzig; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

6.  Differential microRNA epression in asthma and the role of miR-1248 in regulation of IL-5.

Authors:  Ronaldo Paolo L Panganiban; Mark H Pinkerton; Saumya Y Maru; Sarah J Jefferson; Alanna N Roff; Faoud T Ishmael
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

7.  microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.

Authors:  Jian-Jun Zhao; Jianhong Lin; Tint Lwin; Hua Yang; Jianping Guo; William Kong; Sophie Dessureault; Lynn C Moscinski; Dorna Rezania; William S Dalton; Eduardo Sotomayor; Jianguo Tao; Jin Q Cheng
Journal:  Blood       Date:  2010-01-19       Impact factor: 22.113

8.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

9.  MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells.

Authors:  Minghua Hu; MicroGene Xia; Xiaobing Chen; Zihong Lin; Yajun Xu; Yuedong Ma; Lei Su
Journal:  Dig Dis Sci       Date:  2009-10-15       Impact factor: 3.199

10.  Prioritization of disease microRNAs through a human phenome-microRNAome network.

Authors:  Qinghua Jiang; Yangyang Hao; Guohua Wang; Liran Juan; Tianjiao Zhang; Mingxiang Teng; Yunlong Liu; Yadong Wang
Journal:  BMC Syst Biol       Date:  2010-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.